In clinical studies at a dose of 250 micrograms (total 633 patients) the most frequently observed adverse reactions, at least possibly related to Palonosetron Hydrochloride, were headache (9 %) and constipation (5 %).
In the clinical studies the following adverse reactions (ARs) were observed as possibly or probably related to Palonosetron Hydrochloride. These were classified as common (≥1/100 to <1/10) or uncommon (≥1/1,000 to <1/100). Very rare (<1/10,000) adverse reactions were reported post-marketing.
Within each frequency grouping, adverse reactions are presented as follows in order of decreasing seriousness. (See Table 4.)
Click on icon to see table/diagram/image
View ADR Monitoring Form